Verve Therapeutics Scoops Up $94M

The round was led by Wellington Management Company and co-led by Casdin Capital, existing investors. New investors in the raise included Redmile Group, Janus Henderson Investors, Cormorant Asset Management, Rock Springs Capital, Novo Holdings A/S, Logos Capital, Surveyor Capital (a Citadel company), RA Capital Management, and a U.S.-based, healthcare-focused fund, alongside additional existing investors GV and Biomatics.

Proceeds from the financing will be used to advance the company's pipeline of gene editing medicines, led by VERVE-101, and further extend its scientific and technical leadership. Verve is developing VERVE-101, comprised of a messenger RNA for adenine base editing and a guide RNA for PCSK9 gene targeting, packaged in a lipid nanoparticle delivery vehicle, for the initial treatment of heterozygous familial hypercholesterolemia (HeFH), a potentially fatal genetic heart disease.

Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve's gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. For more information, visit www.VerveTx.com.